Administrative Supplement: COBRE in Pharmaceutical Research and Innovation

行政补充：COBRE 药物研究与创新

• 批准号: 10582060
• 负责人: Jon Scott Thorson
• 金额: $ 25万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10582060
• 关键词: Address; Administrative Supplement; Area; Award; Biology; Biomedical Research; Bone Regeneration; Bone Tissue; Cardiovascular Diseases; Centers of Research Excellence; Chemicals; Clinical; Collaborations; Communicable Diseases; Communication; Core Facility; Development; Devices; Discipline; Disease; Education; Environment; Faculty; Fostering; Funding; Goals; Health; Infrastructure; Kentucky; Malignant Neoplasms; Mentors; Mentorship; Modeling; Molecular Medicine; Organic Synthesis; Outcome; Parents; Pharmacologic Substance; Pharmacy facility; Phase; Pilot Projects; Research; Research Personnel; Research Project Grants; Research Support; Science; Scientist; Testing; Therapeutic; Translational Research; Translations; Universities; Validation; career development; clinical application; college; experience; faculty research; innovation; interdisciplinary collaboration; interest; multidisciplinary; pre-clinical; pre-clinical research; prevent; tool

SUMMARY/ABSTRACT OF FUNDED PARENT AWARD (P20 GM130456) The Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation (CPRI) at the University of Kentucky (UK) is a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. This Phase I COBRE leverages and develops unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Key COBRE infrastructure to be developed and implemented in Phase I includes the CPRI Administrative Core and two research support cores (the Translational Core and the Computational Core) and the COBRE will also further develop and leverage the COBRE for Molecular Medicine’s Organic Synthesis Core to support CPRI junior faculty projects/pilots. CPRI currently supports four outstanding junior investigators working in three therapeutic areas (cancer, infectious disease and tissue/bone regeneration). Our overarching hypothesis is that CPRI’s translational chemical biology focus presents a distinctly unique UK platform to: i) engage, integrate and mentor junior faculty from a broad range of fundamental, applied and clinical disciplines; ii) facilitate the development of new impactful probes/tools/models and advance innovative transdisciplinary research; and iii) bridge the gap between basic academic research discoveries and commercial/clinical application via education, mentorship and key support infrastructure. CPRI’s distinct focus on translational chemical biology and early translation fills a notable preclinical research gap for many of UK’s exceptional research centers strategically focused on understanding, treating and preventing the major diseases that contribute to Kentucky’s disproportionate health challenges. Anticipated COBRE outcomes include an increase in the number and diversity of UK junior faculty engaged in translational chemical biology research and better-prepared to develop and employ innovative biomedical probes/tools/models/materials, new sustainable UK translational chemical biology research support infrastructure and capabilities, an increase in the number of UK junior faculty with independent research funding, and a boost in the number potentially ‘translatable’ UK preclinical assets.

受资助家长奖摘要/摘要 (P20 GM130456) 药物研究与创新卓越生物医学研究中心 (CPRI) 肯塔基大学（英国）是一所专注于转化化学的综合性多学科中心 生物学 [化学生物学的联系（应用化学生物学原理开发经过验证的 探针/模型以增进我们对生物学的理解）和药物科学（应用 推进解决未满足的临床需求的药物原则）]。 COBRE 利用并开发独特的转化化学生物学研究支持基础设施/专业知识 促进初级教师的指导和职业发展、创新生物医学研究 探针/工具/模型/材料的开发和验证，以及潜在“可翻译”的早期进展 第一阶段将开发和实施的主要 COBRE 基础设施包括 CPRI 管理系统。 核心和两个研究支持核心（翻译核心和计算核心）和 COBRE 将 还进一步开发和利用 COBRE 分子医学的有机合成核心来支持 CPRI CPRI 目前支持四名杰出的初级研究员在三个项目中工作。 领域（癌症、传染病和治疗组织/骨再生）。 我们的首要假设是，CPRI 的转化化学生物学重点呈现出一种独特的 英国平台：i）吸引、整合和指导来自广泛的基础、应用和 临床学科；ii) 促进新的有影响力的探针/工具/模型的开发并推进创新 跨学科研究；以及 iii) 弥合基础学术研究发现与 通过教育、指导和关键支持基础设施实现商业/临床应用。 关于转化化学生物学和早期翻译的研究填补了英国许多研究机构的显着临床前研究空白 卓越的研究中心战略性地专注于了解、治疗和预防主要疾病 导致肯塔基州面临不成比例的健康挑战的因素包括： 英国从事转化化学生物学研究的初级教师数量和多样性的增加 为开发和使用创新的生物医学探针/工具/模型/材料、新的可持续发展做好更好的准备 英国转化化学生物学研究支持基础设施和能力，数量增加 英国初级教师拥有独立研究经费，并且潜在“可翻译”英国的数量有所增加 临床前资产。